From the Journals

GLP-1 RAs Linked to Higher Hair Loss Risk

A large matched cohort study quantifies the association between glucagon-like peptide-1 receptor agonist use and nonscarring alopecia

Share

A multicenter cohort study published in JAAD International found that adults utilizing glucagon-like peptide-1 receptor agonists (GLP-1 RAs) face significantly higher odds of nonscarring hair loss after 6 and 12 months compared to matched controls. The research utilized data from the TriNetX US Collaborative Network, examining patients aged 12-89 treated with these medications from 2014-2024. Key findings indicate increases in telogen effluvium and androgenetic alopecia among GLP-1 RA users, suggesting a need for awareness and monitoring amidst potential confounding factors.

Original Source(s)

GLP-1 RAs Linked to Higher Hair Loss Risk

A large matched cohort study quantifies the association between glucagon-like peptide-1 receptor agonist use and nonscarring alopecia

  • by Kerri Miller

  • February 19, 2026

  • 3 min

Related Content

Combo Therapy for Psoriasis With Obesity

A phase 3b trial tests ixekizumab plus tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight.

Apocrine Gland Changes in Early Hidradenitis Suppurativa

Weight Loss Drugs Reshape Facial Surgery: Survey

AAFPRS survey reveals GLP-1 medications drive 50% increase in fat-grafting procedures as patients seek solutions for weight loss-related facial volume loss.